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Background:
Follicular cell-derived thyroid
carcinomas harboring RET/PTC oncogenes are
immunostimulatory and highly curable, despite
activating RAS/BRAF/MEK/ERK and PI3K/AKT.
Results: RET/PTC oncoproteins associate with
TRAFs to mediate cytokine production but not
transformation.
Conclusion: The RET/PTC:TRAF pathway is
functionally separable from the RET/PTC-induced
MEK/ERK and PI3K/AKT pathways.
Significance: Understanding RET/PTC-mediated
immunostimulation could provide new strategies
for treating more aggressive forms of thyroid
carcinoma.

Eliminating this mechanism reduces proinflammatory cytokine production without
decreasing
transformation
efficiency.
Conversely, ablating MEK/ERK or PI3K/AKT
signaling eliminates transformation but not
pro-inflammatory
cytokine
secretion.
Functional uncoupling of the two pathways
demonstrates that intrinsic pro-inflammatory
pathways are not required for cellular
transformation and suggests a need for further
investigation into the role inflammation plays in
thyroid tumor progression.
Inflammation can contribute to late phases of
cancer progression by enhancing viability,
angiogenesis and metastasis (1, 2). The notion
that inflammation can also be an important early
event during neotransformation is based upon the
positive correlation observed between pre-existing
chronic inflammatory conditions and cancer
incidence (1-3); and the observed effects of antiinflammatory compounds modulating cancer
development (4) Thus, it has been suggested that
activation of the NF-κB family of transcription
factors promotes mitogenicity by triggering
cytokine
secretion
from
neoplasia
and
inflammatory infiltrates while supporting tumor
viability through inhibition of apoptotic pathways
(5). Additionally, inflammatory infiltrates have the
potential to induce reactive oxygen species and

SUMMARY
Thyroid carcinomas that harbor RET/PTC
oncogenes are well differentiated, relatively
benign neoplasms compared to those expressing
oncogenic RAS or BRAF mutations despite
signaling
through
shared
transforming
pathways. A distinction, however, is that
RET/PTCs
induce
immunostimulatory
programs, suggesting that, in the case of this
tumor type, the additional pro-inflammatory
pathway reduces aggressiveness.
Here we
demonstrate that pro-inflammatory programs
are selectively activated by TRAF2 and TRAF6
association with RET/PTC oncoproteins.
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such an oxidative environment could promote
oncogenic mutations (6). Yet, NF-κB itself is not
an oncogene and tissue specific autoimmunity in
the absence of cancer often exists in patients for
extensive periods. Therefore, the requirement for
inflammation during initiation and early stages of
tumorigenesis remains unclear (1).
Papillary thyroid carcinoma (PTC), the most
prevalent endocrine cancer worldwide (7), is
particularly attractive for exploration of this issue.
PTCs that progress to become more aggressive
follicular
cell-derived
thyroid
carcinomas
(FDTC), such as follicular thyroid carcinoma
(FTC) and anaplastic thyroid carcinoma (ATC)
are generally associated with point mutations in
RAS small GTPases or BRAF serine/threonine
kinases, respectively (2, 8). The more indolent
PTCs are associated with radiation-induced
RET/PTC oncogenes that encode fusions of the
RET receptor kinase domain with one of several
different dimerizing proteins, resulting in a
constitutively active kinase (9).
The most
prevalent RET/PTC isoforms are RET/PTC1
(RP1) and RET/PTC3 (RP3) consisting of either
H4/CCDC6 or ARA70/ELE1 as the respective Nterminal dimerizing partner (10)(10)(10) (10-12).
RET/PTC
oncogenes
activate
both
RAS/BRAF/MEK/ERK and PI3K/AKT pathways
that are crucial for thyrocyte transformation (1315), yet are associated with a high cure rate and
low tumor recurrence. In contrast, the more
aggressive FDTCs usually harbor oncogenic RAS
or BRAF point mutations and are associated with a
poorer prognosis and higher recurrence rate (2, 8).
Notably,
FDTC
harboring
RET/PTC
oncogenes display an immunostimulatory profile
(14, 15) and is associated with the development of
autoimmune thyroiditis (16-21). Conversely, the
more aggressive and poorly differentiated FDTCs,
expressing oncogenic RAS or BRAF point
mutations, are characterized by tumor-promoting
immune responses such as the infiltration of
immunosuppressive macrophages (22). Although
the mechanistic basis for RET/PTC-induced
immunostimulation is currently unclear, it is
thought to involve members of both the classical
and alternative pathways of NF-κB through the
stabilization of NIK kinase (23-25).

Since RET/PTC oncoproteins activate
RAS/BRAF/MEK/ERK, PI3K/AKT, and NF-κB
signal transduction pathways, this tumor type
might be expected to be highly proliferative and
readily progress to a less differentiated cancer
such as anaplastic carcinoma.
However,
RET/PTC-expressing PTCs tend to be rather
indolent and expression in poorly-differentiated
and anaplastic thyroid carcinomas are rare (26).
Thus, in the case of PTC, one interpretation of this
process is that the additional immunostimulatory
program is detrimental to the progressing tumor.
To resolve this conundrum, our primary goal was
to determine whether proinflammatory cytokine
release and cellular transformation proceed along
the same signaling pathways, or whether the two
processes are functionally distinct and separable.
The latter would permit investigation of whether
the RET/PTC-induced proinflammatory program
is necessary for transforming events as well as
exploration of the mechanistic link between
RET/PTC expression and NF-κB activation. The
results of our investigations provide insight into
the early stages of thyroid oncogenesis that could
influence future approaches to the treatment of all
types of FDTC.
Experimental Procedures
Chemical Reagents: All cell culture and
chemical reagents were purchased from Sigma
unless stated otherwise.
Cloning: mRP3.51 (RP3) was previously
constructed and cloned into a bacterial expression
vector (27). To perform the following studies RP3
was excised from the pET29a vector and cloned
into the mammalian expression vectors Rc/CMV
and MSCV.IRES.GFP. A Kozak consensus and a
TAA stop sequence were placed 5’ and 3’ of the
RP3 cDNA. All RP3 mutants were created by
site-directed mutagenesis using Quikchange II
(Stratagene)
according
to
manufacturer’s
instructions. MSCV.IRES.mRFP was created by
excising the GFP sequence and replacing it with
the sequence for monomeric RFP. The sequences
encoding TRAF2 and TRAF6 blocking peptides
(T2pep and T6pep) and control peptides (T2cntl
and T6cntl) were synthesized by IDT, amplified
by PCR and cloned into MSCV.IRES.mRFP.
3

Cell Culture: TPC-1 and PCCL3 cells were
kindly provided previously by Dr. Massimo
Santoro.
NIH-3T3 (kindly provided by Dr.
Tschiclis, Tufts University), 293T (ATCC), and
TPC-1 cell lines were maintained in DMEM
media with 10% FBS (D10). The rat PCCL3
thyroid cell line was maintained in F12 media
containing 5x10-3 IU/ml bovine TSH, 5 µg/ml
bovine
insulin,
10
ng/ml
Gly-His-Lys,
somatostatin 10 ng/ml, apo-transferin 5 µg/ml, 10
nM hydrocortisone, and 10% FBS (F12+).
PCCL3 cells require thyroid stimulating hormone
(TSH) for cell growth under basal conditions and
exhibit TSH-independent growth upon expression
of RET/PTC. However, since removing TSH can
alter the ability of thyrocytes to produce
inflammatory cytokines (28-30), all PCCL3
treatments were maintained in the same culture
conditions. For all experiments PCCL3 cells were
treated in a 1:1 ratio of F12 media and D10. All
cells were maintained in a 37oC incubator at 9%
CO2.
For the generation of stable lines:
Retrovirus was prepared by co-transfecting 293T
cells
with
pCL-Eco
and
indicated
MSCV.IRES.GFP
or
MSCV.IRES.mRFP
constructs with Fugene 6 (Roche). At 24 hr posttransfection, fresh medium was replaced and viral
supernatant was collected at 24, 48, and 72hr. For
viral transduction, cells were plated at 5x10^4
cells/well in 6-well plates and treated with prefiltered viral supernatant diluted 1:2 in DMEM
containing 10% FBS and 8 µg/ml polybrene. At
24 hr post-transduction viral supernatant was
replaced with fresh 10% media and sorted for GFP
or monomeric RFP expression on day 3. For
maintenance of cell lines: NIH-3T3 transductants
were maintained in D10 while all PCCL3
transductants were maintained in 1:5 ratio of
F12+:D10.
TSH, insulin, Gly-His-Lys,
somatostatin, apo-transferin, and hydrocortisone
were all from Sigma.
U0126 (Cell Signaling
Technology) was chosen based on its high
selectivity to both MEK1 and MEK2 (versus
PD098059 which inhibits MEK1), and used at 10
µM at all indicated times based on previously
published results (31). LY294002 (Cell signaling
Technology) was chosen based on its high
selectivity to PI3K and used at 10 µM to

demonstrate PI3K/AKT inhibition in the absence
of apoptosis/toxicity (32, 33).
Transient Transfection and siRNA knockdown:
For cytokine analysis of PCCL3 cells, 105
cells/well were plated in 6-well tissue culture
plates. The next day cells were transfected with
Genejuice (EMD Chemicals) at a 3:3 ratio of
reagent (µl):DNA (µg). After 48 hr, total RNA
(Machery-Nagel) or cytosolic protein was
harvested for RT-PCR or western analysis. For
TRAF knockdown of TPC cells, TRAF2 siRNA
and TRAF6 siRNA (Santa Cruz) were transfected
at 25 nM with siRNAMAX (Invitrogen) and on
day 2 was harvested for ELISA, RT-PCR, or
western analysis or subsequently treated and
harvested on day 4 as indicated.
RT-PCR: Total RNA was extracted using the
Nucleospin RNA II kit (Macherey-Nagel).
Reverse transcriptase-PCR was performed on 0.52 µg of total RNA using Superscript II
(Invitrogen)
according
to
manufacturer’s
instructions. PCR was performed for 30 cycles at
60oC.
Western Blot Analysis and Immunoprecipitations: All cells were lysed with 150 mM
NaCl, 20 mM Tris-Cl, 1% Triton X 100, pH 7.2
containing 1X HALT protease inhibitors with
EDTA (Pierce) and 1X HALT phosphatase
inhibitors (Pierce). Lysates were quantified using
BCA kit (Pierce). For immuno-precipitation:
Pre-cleared 500 µg total protein was incubated
overnight with anti-RET antibody and Protein Gsepharose beads (Pierce). Subsequently, beads
were washed with cell lysis buffer three times and
eluted with 100 mM glycine (pH 2.7). Eluted
material was neutralized with 1M Tris pH 8.8,
combined with 6X loading buffer, and run on 12%
SDS-PAGE gel. For Western analysis: 10 µg of
total protein was loaded onto a 12% SDSpolyacrylamide gel. Gels were blotted for 1 hr at
100V onto nitrocellulose membranes (GE
Biosciences) and blocked for 30 min with 5%
milk/TBS + 0.1% Tween.
All blots were
incubated overnight with the indicated antibody,
washed and stained with anti-rabbit-HRP (Cell
Signaling), donkey anti-mouse-HRP or donkeyanti-goat-HRP (Jackson Immunoresearch). All
indicated antibodies were from Cell Signaling
Technology aside from anti-phospho-RET (1062),
4

anti-RET (C-20), and anti-TRAF6 (H274) which
were from SantaCruz Biotechnology.
Macrophage Chemotactic Protein MCP-1
ELISA: A 96-well Maxisorp plate (Millipore) was
coated at 2 mg/ml with anti-CCL2 antibody
(eBioscience), overnight 4oC. The plate was
blocked with 1% BSA/PBS and cell culture
supernatants were incubated in duplicate wells
overnight at 4oC. The next day, plates were
washed with PBS/0.05% Tween 20 and incubated
with
biotinylated
anti-CCL2
antibody
(eBioscience) for 2 hr, 27oC, washed, stained with
1:1000 Streptavidin-HRP (BD Bioscience) for 1
hr, 27oC, and developed with 2 mg/ml OPD
(Sigma) according to manufacturer’s instructions
and visualized at 405 nm in a spectrophotometer
(Victor2 by Wallac 1420 multilabel counter).
Cell Proliferation: PCCL3 and TPC-1
transductants were cultured in triplicate at 1000
cells per well in 96-well flat bottom plates in D10
media in the absence of hormones. Viable cells
were counted daily by trypan blue exclusion.
Soft Agar Assay: 5x103 stable GFP-expressing
NIH-3T3 lines were suspended in 0.25% agarose
in 1X MEM + 10% FBS with 1 X
penicillin/streptomycin
(Gibco)
and
1X
gentamicin (Gibco) and plated in triplicate over a
layer of pre-set 0.5% agarose in 1X MEM + 10%
FBS with 1 X penicillin/streptomycin and 1X
gentamicin in 6-well plates. 20 days after plating
the cells were photographed and analyzed for
colony number and size or stained for 1 hour at
27oC with crystal violet in PBS and photographed
over a light box. For quantification of colony size,
5 photographs were taken per well using a Nikon
Eclipse TE 2000-U camera attached to a confocal
microscope. 1 photograph/1 cm2 block was taken
using a grid that was partitioned in 1 cm2 sections
was . The longest length of the colonies was
measured in µm using the NIS Elements Version
2.3 program. The sum of the number and length
of the colonies was calculated per well and the
mean and standard deviation of triplicate wells
was calculated per condition (total of 15
photographs taken per condition).

induction. Both RP1 and RP3 activate similar
oncogenic and inflammatory programs (14, 15, 25,
34) and this trait is attributed to the constitutively
active C-terminal RET kinase domain that is
shared by all RET/PTC variants (35, 36).
Therefore, we utilized an immortalized rat thyroid
cell line, PCCL3, transiently transfected with RP3
to examine early activation of proinflammatory
cytokine transcription.. Early phase induction
occurs within the first 48 hr of expression and
drives ectopic production of MCP1 in abundant
quantities and IL6 to a lesser extent (34). To
determine whether this early cytokine induction is
dependent upon PI3K/AKT or MEK/ERK
signaling, PCCL3 cells were transfected with the
highly related mouse homologue of RP3 (RP3WT)
and treated with selective pathway inhibitors. As
demonstrated in Fig. 1A, the PI3K inhibitor
LY294002 (LY) or with the MEK1/2 inhibitor
U0126 (U0) did not disrupt early transcriptional
induction of MCP1 or IL6 by RP3. As a control
for protein expression, RP3K284M, which is devoid
of all kinase activity (37, 38), was examined and
demonstrated no increase in AKT, ERK, or
proinflammatory cytokine activity. Furthermore,
RP3 transfected cells treated with LY or U0 and
cells transfected with RP3K284M exhibited less cell
scattering,
indicative
of
increased
cell
mobilization, and less transformation when
phenotypically compared to cells transfected with
RP3WT (Fig. S1A). The inhibition of DUSP6
induction by U0 and activation of the sodium
iodide symporter (NIS) expression by U0 and LY,
demonstrate that the inhibitors were effective at
disrupting their respective pathways (Fig. 1A).
Furthermore, western blot analysis revealed that
treatments with LY and U0 led to a dramatic
decrease in phosphorylation of AKT and ERK,
respectively (Fig. 1B).
Similar experiments were then performed to
determine the influence of the AKT and ERK
pathways on late phase cytokine expression. After
long-term expression in thyrocytes, RET/PTC
induces a milieu of proinflammatory cytokines
that include MCP1, IL6, IL8, TNFα, IL1α, IL1β,
CXCL10, M-CSF and GM-CSF (14). The TPC-1
cells line is derived from human papillary thyroid
carcinoma, constitutively expresses RP1, and
produces these same proinflammatory cytokines.
TPC-1 cells treated with LY or U0 exhibited no

RESULTS
Chemical inhibition of PI3K and MEK1/2
does not decrease RET/PTC-mediated cytokine
5

(Fig. 2B). With respect to the reverse phenotype,
(transformation without proinflammatory activity)
three substitutions, RP3K284M, RP3Y431F, and
RP3Y478F, resulted in ablation of early phase RP3induced MCP-1 production from transiently
transfected PCCL3 cells (Fig. 2A). This was
somewhat expected for RP3K284M and RP3Y431F
since both encode proteins with catalytically
inactive kinase domains based on the crystal
structure and biochemical analysis of RET (39,
45). In contrast, altered MCP-1 induction by
RP3Y478F was not anticipated and the downstream
effect of this mutation on other RP3 regulated
signaling pathways was investigated by western
blot analysis. As shown in Fig. 2C, compared to
the other mutations, RP3Y478F enabled activation of
both AKT and ERK pathways to the same degree
as RP3WT. These findings prompted a closer
evaluation of the protein interactions at or adjacent
to the Y478 region.
TRAF2 and TRAF6 associate with RP3 in a
kinase-independent manner. To identify potential
candidates as binding partners at or near Y478, the
full length sequences of human, mouse, and rat
RP3 were screened online at the Eukaryotic Linear
Motif (ELM) site (http://elm.eu.org/) (46) using
protein structure, cell compartment (cytosol), and
taxonomic (human, mouse, and rat) filters.
Consequently,
the
sequence
482-487
(GIPPERLF), adjacent to Y478, was identified as
a potential binding site for TRAF6 and 560-564
(SEEE) was designated as a site for TRAF2.
TRAF2 and TRAF6 are members of the TRAF
(TNF Receptor Associated Factor) family of E3
ubiquitin ligases that initiate either classical or
alternative NF-κB signaling cascades from TNFR
family members, TLRs, and other cell surface
receptors such as NGFR and TGFβR to promote
proinflammatory cytokine production (47).
The GIPPERLF site is situated within a
surface soluble disordered loop (45) suggesting
that this region is accessible to cytosolic binding
partners, and the SEEE motif also appears to be
located within disordered regions according to the
ELM site and the online program GlobPlot
(http://globplot.embl.de/) using Deleage/Roux or
Russell/Linding set parameters (48). To determine
whether TRAF proteins associate with RET/PTC,
293T cells were transiently transfected with RP3
and
cell
lysates
were
subjected
to

loss of MCP1, IL6, and TNFα transcript
production after 48 hrs (Fig. 1C). In fact, it
appears that inhibition of ERK activity actually
increases
cytokine
transcription.
This
phenomenon was also observed at the protein level
(Fig. S1C), suggesting that a potential negative
feedback role of MEK/ERK exists to reduce
RET/PTC-mediated late phase cytokine secretion.
Again, these compounds effectively disrupted
intended components in these signaling pathways
as indicated by western blot analysis (Fig. 1D),
reduced transformed phenotype, and decreased
cell proliferation (Figs. S1B and S1D). We did
observe decreased MCP-1 secretion from LY
treated cells (Fig. S1C), however this decrease
was attributable to a reduction in total cell number
(Fig. S1D). Together these results support the
idea that ectopic cytokine secretion is a common
feature of RET/PTC variants (14, 34), and support
the notion that this genetic program is not
dependent upon PI3K/AKT and MEK/ERK for
early or late phases of cytokine secretion.
Proinflammatory and mitogenic signaling
pathways originate from distinct regions of the
RP3 oncoprotein. The observation that RP3mediated early and late inflammatory programs
are not dependent upon AKT and ERK signaling,
led us to investigate whether the inflammatory and
mitogenic pathways could be uncoupled through
genetic approaches. Mass spectrometric analysis
had previously determined that at least 8 of 16 key
tyrosine residues are autophosphorylated during
RET activation (39), and RP3 contains all 8
proposed signaling tyrosines.
Therefore, we
generated a panel of YF substitutions and
screened for the ability of these mutants to induce
early cytokine production from PCCL3 cells. One
of these mutations, Y588F, is known to be needed
for PI3K/AKT and RAS/BRAF/MEK/ERK
signaling (40-43). If functional separation is
possible, a mutation could demonstrate
proinflammatory activity in the absence of AKT or
ERK activity. Indeed, both RP3WT and RP3Y588F
induced equal amounts of MCP-1 (Fig. 2A),
indicating that the inflammatory pathway does not
initiate from Y588. Since it has been reported that
Grb2 binds the Y622 site (44), although it does not
appear to contribute to ERK activity (40),, we
additionally tested a Y588F/Y622F double mutant
and did not detect decreases in MCP1 production
6

immunoprecipitation with an anti-RET antibody
specific for the last 51 amino acids of the Cterminus.
As shown in Fig. 3B, TRAF2 and
TRAF6 co-precipitate with RP3WT without
additional cross-linking indicating a specific
association. Additionally, TRAF2 and TRAF6
binding to RP3Y588F is equivalent to that of RP3WT,
while RP3Y478F exhibits decreased association to
TRAF6 (Figs. 3C&D). Of note, TRAF2 and
TRAF6 bind equally well to the kinase dead
mutant, RP3K284M, indicating that binding is
independent of kinase activity (Figs 3B-D).. To
determine the requirements for TRAF interaction,
we created truncated mutants of RP3 (Fig. 3A).
RP3∆N lacks the autodimerizing N-terminal
segment (residues 1-238) and RP3∆TK2 lacks the
second tyrosine kinase domain of RET (residues
338-589) in which the TRAF-binding motifs are
predicted to reside. No association was detected
with RP3∆TK2, while association of TRAF2 and
TRAF6 was detectable with RP3∆N, only after
prolonged exposure of the blot but beyond the
linear range of detection compared to the RP3WT
signal (unpublished data) (Fig. 3B).
These
findings suggest that, although TRAF binding is
independent of kinase function, TRAF association
is still dependent upon RP3 dimerization (model in
Fig. 7). Furthermore, the absence of TRAF
association with RP3∆TK2 suggests that TRAF or
TRAF-binding adaptor proteins associate within
residues 338-589. We confirmed the specificity of
the association by examining the endogenous
interaction of TRAF2 and TRAF6 to RP1 in the
TPC-1 cell line. Fig. 3G demonstrates that
immunoprecipitation of RP1 can pull down both
TRAF2 and TRAF6; suggesting that TRAF
association is most likely occurring in the Cterminus derived from RET.
To dissect the specificity of TRAF2 and
TRAF6 binding, the putative sites were altered
from SEEE to SEAA (RP3T2mut) and GIPPERLF to
GIQPARLA (RP3T6mut). Examination of RP3T2mut
showed decreased binding to TRAF2 compared to
RP3WT with no effect on TRAF6 association (Fig.
3D), while RP3T6mut demonstrated decreased
binding to both TRAF2 and TRAF6 (Fig. 3E). In
contrast to the ∆N and ∆TK2 truncations, none of
the tested mutations completely ablated TRAF
association, suggesting that there are additional

points of contact within the binding sites or that
RP3 contains additional binding sites for TRAFs
and/or TRAF-associated adaptors. Overall these
findings further support the idea that
proinflammatory signaling is initiated at TRAFbinding sites through a mechanism that is distinct
from Y588-mediated pathways.
The RP3-induced TRAF-mediated production
of proinflammatory cytokines is independent of the
RAS/BRAF/MEK/ERK and PI3K/AKT pathways.
Since TRAF oligomerization is known to activate
NF-κB family members and subsequent cytokine
induction, we investigated whether TRAF
signaling was responsible for production of
cytokines from RET/PTC-transformed cells. As
shown in Figs. 4A-C, siRNA knockdown of either
TRAF2 or TRAF6 substantially decreased MCP1
production. Induction of other cytokines was also
reduced, GMCSF > IL8 > IL6 > TNFα. This
change in inflammatory profile was regulated
mainly, if not entirely, at the transcriptional level
as demonstrated by RT-PCR (Figs. 4A-B). To
confirm the reduction of cytokine secretion,
supernatants were harvested from TPC-1 cells on
day 2 and day 4 after siRNA treatment and tested
in a specific MCP1 ELISA. As shown in Fig. 4C,
MCP1 protein secretion by TRAF siRNA-treated
cells was greatly reduced in a time dependent
manner compared to siRNA control.
Additionally, we examined the ability of
TRAF-inhibiting peptide sequences to knockdown
cytokine secretion over a longer period of time.
The TRAF2 peptide sequence designed from
CD40, AYPIQETA (T2pep), and the TRAF6
sequence designed from RANK, APTEDEYA
(T6pep), as well as their controls (AYAIAATA
and AATADAYA) were overexpressed using
MSCV.IRES.mRFP viral vectors and stable
transductants were selected by cell sorting for
RFP. Fig. 4D demonstrates that inhibition of
TRAF2 oligomerization via overexpression of the
TRAF2 binding motif greatly reduce cytokine
expression in TPC-1 cells. Overexpression of
T6pep did not reduce MCP1 induction to the same
extent as T2pep and may reflect a decreased
affinity of this peptide for its target.
We further examined the cytokine profile of
PCCL3 cells stably expressing the RP3 mutants.
As observed in Fig. 4E, it appears that ablation of
MCP1 production was not maintained with
7

sustained expression of RP3Y478F or RP3T2mut;
however, this is in contrast to the RP3T6mut, in
which the long-term production of MCP1 was
greatly reduced. This result may reflect the fact
that the RP3Y478F or RP3T2mut mutations do not
completely ablate TRAF binding although the
association is reduced.
We next determined whether TRAF2 or
TRAF6 contribute to either AKT or ERK
signaling. As predicted by our original findings,
TPC-1 cells treated with siRNA specific for
TRAF2 or TRAF6 showed no decrease in the
phosphorylation levels of AKT or ERK (Fig. 5A).
Indeed, it appears that TRAF2 signaling
negatively
regulates
PI3K/AKT
and
RAS/RAF/MEK/ERK pathways since there is
increased phosphorylation of AKT and ERK in the
absence of TRAF2 (Fig. 5A). In addition, longterm expression of TRAF2 and TRAF6 blocking
peptides does not affect AKT and ERK activity or
cellular proliferation relative to the peptide
controls (Figs. 5B-C). Furthermore, it appears
that TRAF2 knockdown (Fig 5A) or T2pep
expression (Fig 5C) leads to decreased NIK kinase
stability. This finding is consistent with recent
studies showing that RP3 promotes the
stabilization of NIK to activate the canonical
pathway of NF-κB (23). Together these findings
suggest that RET/PTCs induce a TRAF-dependent
proinflammatory program in thyroid cells and this
pathway is independent of PI3K/AKT and
RAS/BRAF/MEK/ ERK activity.
TRAF-deficient RP3 mutants maintain
transforming properties. Our data indicate that the
TRAF-mediated pathway is spatially and
functionally distinct from the PI3K/AKT or
RAS/BRAF/MEK/ERK pathways.
Previous
results have reported that point mutations within
RAS or BRAF are sufficient to drive
transformation of thyroid follicular cells (8).
Based on our results above, we hypothesized that
disrupting the TRAF pathway should have little to
no impact on transformation.
To test this
prediction, we examined whether the TRAFdeficient mutants were capable of maintaining
hormone independent growth. In accordance with
our observation that TRAF-deficient mutants
maintained ERK and AKT activity, PCCL3 cells
stably transduced with RP3Y478F, RP3T6mut, and
RP3T2mut demonstrated hormone-independent

growth comparable to RP3-transduced cells (Fig
5D). We further examined the ability of the
TRAF-deficient mutants to promote anchorageindependent growth.
NIH-3T3 cells were
transduced with GFP-tagged retroviral constructs
encoding wild-type or mutated RP3, sorted for
GFP expression, and examined for colony growth
in soft agar. After 20 days of growth, the colonies
were stained with crystal violet (Fig. S2) or
photographed for measurement of colony size
(Figs. 6A-B). Most notably, the TRAF-deficient
mutants, RP3T6mut and RP3T2mut induced colonies
in size and number comparable to wild type RP3
(Figs. 6A-B). In contrast, RP3K284M, RP3Y431F, and
RP3Y588F produced little to no colonies. We
confirmed that the lack of colony formation was
not due to loss of gene expression (Fig. S3).
Interestingly, the Y478 mutation resulted in
transductants with compromised transformation
properties compared with RP3WT (Figs. 6A-B).
The lack of inflammatory cytokine production
by RP3T6mut and RP3T2mut transfectants may limit
their capacity to form tumors in vivo due to the
lack of induced stromal support (49). To test this
notion, immunodeficient RAG-/- mice were
subcutaneously injected with the NIH3T3
transductants described above and monitored for
tumor growth. Fig. S6 shows that mice injected
with RP3WT, RP3T6mut, or RP3T2mut transfectants
rapidly developed palpable tumors after 13 days,
while mice injected with NIH3T3 expressing GFP
alone showed no tumor growth. Mice that
received RP3K284M or RP3Y588F cells did not grow
significantly measurable tumors. Interestingly it
appears that the RP3T6mut transductants produced
smaller tumors which may reflect the smaller
colony size in Fig. 6B, a decreased influx of innate
cells, or decreased stromal support and
angiogenesis. Further investigation that includes
immunocompetent mice and increased animal
numbers may allow for more detailed insight into
the role that an intrinsic TRAF pathway plays on
in vivo tumor progression. In summary, the results
indicate that RET/PTC-induced TRAF-mediated
proinflammatory cytokine production is not
required for cellular transformation driven by the
PI3K/AKT and RAS/BRAF/MEK/ERK pathways.
DISCUSSION
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The unusual pleiotropic signaling properties of
the RET/PTC oncogenes (14, 24, 34) provide an
attractive model for studying the mechanistic
relationships between oncogene-induced cellular
transformation and proinflammatory pathways.
RET/PTC translocation is thought to be one of the
earliest events in the initiation of papillary thyroid
cancer (9, 50) and ectopic pro-inflammatory
mediators have been presumed to contribute to the
cellular transformation process (2, 3), but this has
not been formally tested for this cancer type. We
report here that TRAF-mediated cytokine
induction and cellular transformation are
functionally distinct in neoplastic thyrocytes, a
finding that will enable a finer resolution of the
components necessary to drive cancer progression.
These data also point to one explanation for why
oncogenes such as mutant RAS or BRAF do not
exhibit the same degree of immunostimulatory
phenotype and progress along different
pathologies
despite
utilizing
the
same
transforming pathways as RET/PTC-based tumors.
Although stimulatory crosstalk between the
RAS/AKT and NF-κB pathways has been
suggested for lung epithelial cell tumorigenesis
(51), we did not observe positive feedback
mechanisms in our experimental systems. If
anything, TRAF2 mediated signaling appears to
suppress the AKT and ERK signaling pathways
(Fig. 5A). This is in accordance with the
observation that TRAF6 negatively regulates PI3K
activity during T cell activation (52). Additionally
the signaling dichotomy we demonstrate here has
recently been shown for MIG-6 tumor suppressor
expression in PTC. These studies demonstrate that
MIG-6 overexpression in PTC tumor samples or
the TPC-1 cell line activates NF-κB and inhibits
ERK phosphorylation. Conversely knockdown of
MIG-6 decreased NF-κB nuclear localization and
enhanced ERK activity (53).
PTC rarely harbors coexisting RET/PTC,
RAS, and/or BRAF mutations suggesting that
there is limited functional complementation
between these oncogenes with respect to thyroid
tumor initiation/progression (54-56).
The
experiments reported here demonstrate that
RET/PTC-induced TRAF-mediated inflammation
is not required for transformation. Evidently only
the PI3K/AKT and RAS/BRAF/MEK/ERK

pathways are required to establish and maintain
follicular cell transformation (57), while the
inflammatory pathway that is unique to RET/PTC
translocation may serve to modulate the tumor
environment. This conclusion is supported by
recent evidence demonstrating that the MIG-6
tumor suppressor expression correlates directly
with increased NF-κB activity and inversely with
tumor recurrence, survival, and oncogenic BRAF
mutations (53, 58).
Other studies have demonstrated functional
separation in other cell types such as fibroblasts.
For instance, the NF-κB members, p65 (Rel A)
and c-REL, are not required for RAS-mediated
transformation in fibroblasts, although p65 and cREL signaling can potentiate anchorage
independent growth (59).
Furthermore, our
studies showed that blockade of MEK/ERK and
PI3K/AKT actually enhances inflammatory
cytokine production from thyroid papillary
carcinoma, compatible with the published finding
that oncogenic RAS blocks TNF-induced NF-κB
signaling (60).
Our investigation has revealed that TRAFs
associate with RP3 and activate an inflammatory
program that is independent from the PI3K/AKT
and RAS/BRAF/MEK/ERK pathways. TRAF2
and TRAF6 appear to associate independently of
kinase action (as observed with RP3K284M), while
pro-inflammatory TRAF complexes are formed
only upon a catalytically active conformational
change of the kinase domain (as observed with
RP3WT).
This type of interaction has been
described for TGFβR in which wild type, kinase
dead, and constitutively active TGFβR, all
associate with TRAF6 (61). Since RET/PTC is
constitutively expressed in transformed cells, it is
possible that RET:TRAF complexes will be
present at all times leading to aberrant regulation
of NF-κB. This is distinct from the conditional
activation observed with RET and its ligand
GDNF under physiological conditions. A general
model of RET/PTC signaling, based on our
results, is depicted in Fig. 7. A key feature is the
association of TRAF2 and TRAF6 only after
dimerization of RP3. This is similar to TNFR
family members BAFFR and CD40 which exhibit
TRAF association only after ligand binding (62).
In the case of RP3, conversion to the active
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dimeric conformation (Fig. 7) may result in
increased surface exposure of the TRAF-binding
segments. The observation that mutation of the
putative TRAF6 binding site (RP3T6mut) resulted in
reduced association with both TRAF2 and TRAF6
(Figs. 3D&F) was also of interest. TRAF2 often
forms hetero-complexes with other TRAF family
members (63). Therefore it is possible that TRAF2
interacts directly with TRAF6 at this site or that
this location contains binding motifs for both
TRAF2 and TRAF6. This type of TRAF2:TRAF6
interaction has also been described for the
proinflammatory receptor CD40 (64).
We observed that both TRAF2 and TRAF6
associate with RP3 independent of the Y588 site.
Previous reports suggest that proinflammatory
cytokine production initiates `via a Y588dependent signaling cascade (14, 25). It is
interesting that in the absence of TRAF mediated
pathways, we observed the greatest difference in
MCP1 production compared with other cytokines
whereas MCP1 was the least affected using Y588
mutants (25). Further investigation is required to
assess the relative involvement of a TRAF-, AKT, and ERK-independent/Y588-dependent pathway
in cytokine induction. The RAS/BRAF pathway
has also been implicated in secretion of IL-24, IL8, and other chemokines (65, 66), it is possible that
the quality of the proinflammatory cytokine
induction from a RAS-mediated pathway may lead
to a more immune-suppressive/tumor-promoting
environment. While the additional RET/PTCinduced TRAF-mediated pathway skews the
cytokine
profile
towards
a
more
immunostimulatory phenotype. This change in
cytokine profile may strongly contribute to the
autoimmune thyroiditis that is associated with
RET/PTC-expressing tumors.
Activation of NF-κB by RET/PTC involves
members of the classical and alternative pathways
through the stabilization of NIK kinase (23). NIK
was originally cloned and described as a binding
partner of TRAF2 through two-hybrid screening of
a human B cell cDNA library (67). Subsequently,
TRAF2 and TRAF6 were shown to activate NFκB by inhibiting the constitutive proteolytic
degradation of NIK (63, 67-70). Additionally, the
deregulated constitutive expression of NIK results
in a predominant classical activation of NF-κB

and production of proinflammatory mediators in
vivo (71). In our studies we observed that
knockdown of either TRAF2 or TRAF6 in PTC
abrogates the accumulation of NIK (Fig. 5),
suggesting that RET/PTC activation of TRAF
complexes mediates a pro-inflammatory state
through NIK kinase. The observation that TRAF
knockdown results in depletion of NIK kinase,
with no impact on phosphorylation of AKT and
ERK argues further for functional divergence of
the inflammatory and oncogenic pathways.
Here we propose the possibility that
RAS/BRAF and/or PI3K/AKT pathways are
required for cellular transformation and that the
additional inflammatory property of RET/PTCs
shapes the formation of a relatively indolent tumor
by providing an immunostimulatory/tumorsuppressive inflammatory microenvironment.
This could occur by several potentially
cooperative
mechanisms:
(a).
Autocrine
stimulation by cytokines may retard tumor growth.
RET/PTC-expressing human thyroid cell lines and
thyroids from transgenic animals show substantial
up-regulation of many inflammatory mediators
including IL1α, IL1β, IL6, TNFα, IL8, GMCSF,
and MCP1 (14, 24, 34) and it has been reported
that many of these cytokines can inhibit thyroid
tumor cell growth (72). (b). The composition of
the infiltrate itself may lack the factors required
for progression. More aggressive carcinomas that
harbor RAS or BRAF mutations display a heavy
influx of inflammatory cells but these tend to be
immunosuppressive in nature (22). Indeed, tumorassociated macrophages (TAMs) generally exhibit
alternate (“M2”) activation and are mitogenic,
angiogenic,
and
pro-metastatic
through
mechanisms that include IL10, TGFβ, VEGF, and
matrix metalloprotease secretion, respectively
(73). In contrast, the lymphocytic infiltration
associated with indolent PTC is usually
characterized by a Th1 phenotype (74, 75) that is
not
conducive
to
the
production
of
immunosuppressive TAMS (73) and infiltrating
TAMs are rarely found in less aggressive welldifferentiated thyroid carcinoma (22). (c). The
proinflammatory environment may cause a break
in peripheral tolerance and aid the adaptive arm in
controlling/eliminating the tumor. For example,
CXCR4, STAT1, CIITA and MHC Class II are
also up-regulated by RET/PTC expression in
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RP3T6mut, or RP3T2mut tumors were smaller than the
comparable RP3wt tumors suggesting that
inflammatory mediators may contribute to, but are
not necessary for, tumor growth. Accordingly, the
lack of these cytokines may limit the recruitment
of stromal elements and suppress the likelihood of
growth variants (80).
Consistent with this,
TRAF-mediated NF-κB activation is known to
control cell viability and angiogenesis in many
tumor types (1).
Elucidating the influence of RET/PTC induced
inflammation on thyroid tumorigenesis may lead
to more effective therapeutic strategies for PTC.
For example, following surgery, any residual
RET/PTC harboring tumors may be best
approached by targeting only the PI3K/AKT- and
RAS-mediated pathways, while preserving the
inflammatory component. Conversely, induction
of a “RET/PTC-like” TRAF signaling pathway
within the more aggressive PTCs that feature only
oncogenic RAS and BRAF mutations may convert
such tumors to a more benign form. Alternatively,
if TRAF-mediated NF-κB pathways are found to
play a greater role in angiogenesis and escape
during progression then the therapeutic strategy
should be to knockdown both proinflammatory
and oncogenic arms of RET/PTC signaling.
Experiments are currently underway to test these
possibilities.

human thyroid cells in vivo (34, 76, 77). Together
these molecules provide signals for leukocyte
migration, dendritic cell differentiation, and
antigen presentation. Consistent with this, tumors
derived from RP3 transgenic animals are capable
of rapid growth in SCID mice but not
immunocompetent hosts (78).
Clinically, PTCs harboring active RET
translocations are found co-incident with
autoimmune Hashimoto’s thyroiditis (HT) (1621). This longstanding observation has led to the
hypothesis that HT is a risk factor for PTC and,
furthermore, that HT is a precancerous condition
(2, 3). For the various reasons discussed, we
suggest the converse, that the autoimmune
component is the result, rather than the cause of
RET/PTC transformation. Activation of innate
and adaptive immunity via the TRAF signaling
component of RET/PTC would explain the intense
and persistent peritumoral lymphocytic infiltration
and indolent growth that is often associated with
PTC.
The TRAF-mediated proinflammatory
signaling linked to RET/PTC may also help
explain the concurrent expression of RET/PTC
(21) and the better overall prognosis of thyroid
cancer in HT patients (79).
Although data indicate that TRAF-mediated
pathways are not required for early events in
transformation, the question remains whether these
same TRAF-mediated pathways are required for
later stages of tumor progression. Indeed the
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FIGURE LEGENDS
Fig. 1. Inhibitors of PI3K or MEK do not inhibit RP3-mediated proinflammatory cytokine transcription.
(A) PCCL3 cells were transiently transfected with RP3WT or RP3K284M in the presence of 0.1% DMSO
alone, 10 µM of LY294002 or 10 µM of U0126 for 48 hr and cells were lysed for total RNA followed by
reverse transcription and PCR for rat specific gene products. (B) PCCL3 cells were treated as in (A) and
harvested at 48 hr for total protein and western blot analysis. (C) TPC-1 cells were treated for 48 hr with
0.1% DMSO alone, 10 µM of LY294002 or 10 µM of U0126 and subsequently harvested for total RNA
followed by reverse transcription and PCR for human specific gene products. (D) TPC-1 cells were
treated as in (C) and harvested at 48 hr for total protein and western blot analysis. (A-D) Data
representative of two independent experiments. RevT: Reverse transcriptase; LY: LY294002; U0: U0126
Fig. 2. (A-B) RP3Y478F exhibits reduced MCP-1 expression and maintains AKT and ERK activation. (A)
PCCL3 cells were transiently transfected with Rc/CMV vector alone, RP3WT or RP3YF mutants for 48 hr
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and cells were lysed, total RNA extracted and RNA reverse transcribed and cDNA amplified using rat
GAPDH and MCP1 specific primers. Error bars indicate SEM from at least three independent
experiments. (B) PCCL3 cells were transiently transfected with MSCV.IRES.GFP vector alone, RP3WT,
RP3K284M, or RP3Y588F/Y622F mutants for 48 hr and cells were lysed, total RNA extracted and RNA reverse
transcribed and cDNA amplified using rat GAPDH and MCP1 specific primers. (C) Representative
western blot of two individual experiments of PCCL3 cells that were treated as in (A) and harvested at 48
hr for total protein.
Fig. 3. RP3 associates with TRAF2 and TRAF6 in a dimer-dependent and kinase-independent manner.
(A) Schematic representation of RP3WT, RP3K284M, and truncation mutants. (B-F) 293T cells were
transiently transfected with GFP, RP3WT or RP3K284M, or truncation (∆) mutants for 48 hr, lysed, and
subsequently harvested for immunoprecipitation using an anti-RET.51 specific antibody.
Immunoprecipitated protein was subjected to western blot analysis using antibodies specific for TRAF2,
TRAF6, RET or Actin. (G) TPC-1 cell were lysed and subsequently harvested for immunoprecipitation
using an anti-RET.51 specific antibody. Immunoprecipitated protein was subjected to western blot
analysis using antibodies specific for TRAF2, TRAF6, RET or Actin. Representative of at three
independent experiments.. IP: immunoprecipitation; UB: unbound fraction; hIgG: goat IgG heavy chain.
Fig. 4. Knockdown of TRAF2 and TRAF6 abrogates cytokine expression. (A-B) TPC-1 cells were
transfected with non-targeting control, TRAF2, or TRAF6 siRNA and harvested after 48 hours for total
RNA followed by reverse transcription and PCR using human GAPDH, MCP1, IL6, IL8, TNF, GM-CSF,
TRAF2, TRAF6, and RET/PTC1 specific primers. (A) Representative experiment of cytokine transcript
induction of at least 3 individual experiments. (B) Graphs are represented as densitometric analysis of
band intensity relative to GAPDH and the fold induction of that ratio over scrambled siRNA control.
Error bars indicate SD of samples run in triplicate, in three independent experiments. (C) MCP1
secretion was measured on day 4 by ELISA using culture supernantants derived from TPC-1 cells
transfected with scrambled control, TRAF2, or TRAF6 siRNAs treated on day 0 and retreated on day 2.
(D) TPC-1 cells were transduced with MSCV.IRES.RFP constructs expressing T2 and T6 binding motifs
and their peptide controls. Following selection for RFP, cells were harvested for total RNA followed by
reverse transcription and PCR using human GAPDH and MCP1 specific primers. (E) PCCL3 cells were
stably transduced with RP3WT or RP3YF mutants and after a month of passage in culture, cells were
plated overnight and lysed for total RNA followed by reverse transcription and PCR with rat GAPDH and
MCP-1 specific primers. Represented as densitometric measurements of band intensity relative to
GAPDH and the fold induction of that ratio over RP3. (C-E) Error bars indicate SD of samples run in
duplicate, in two independent experiments. Cntl: non-targeting siRNA control; T2: TRAF2; T6: TRAF6
Fig. 5. Disruption of TRAF2 and 6 pathways does not inhibit AKT and ERK pathways. (A) TPC-1 cells
were transfected with scrambled control, TRAF2, or TRAF6 siRNA and re-treated with siRNA on day 2
and on day 4 were harvested for western blot analysis. (B) TPC-1 cells were transduced with
MSCV.IRES.RFP constructs expressing T2 and T6 binding motifs and their peptide controls. Following
selection for RFP, cells were harvested for western blot analysis. (C) Cell proliferation assay of
transduced TPC-1cells from (B) that were plated at 1000 cells/well in 96-well culture dishes and counted
daily. (D) ERK-dependent hormone-independent cell proliferation assay of transduced PCCL3cells
expressing wild type RP3 and mutants. Cells were plated at 1000 cells/well in 96-well culture dishes in
the absence of 6 hormones (TSH, insulin, Gly-His-Lys, somatostatin, apo-transferin, and hydrocortisone
) and counted daily. Data are representative of three independent experiments. Cntl: non-targeting
siRNA control; T2: TRAF2; T6: TRAF6
Fig. 6. TRAF-deficient RP3 mutants maintain transforming activity. (A) Representative photographs of
anchorage-independent colony growth of NIH-3T3 cells stably transduced with RP3WT and mutants used
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for the analysis in (B). (B) Number of colonies counted from a defined grid that were produced from
NIH-3T3 transductants as in (A) that were greater than 100 µm in length and averaged over triplicate
wells. The table below the graph represents the average colony length and standard deviation of the
triplicate wells. Representative of two independent experiments.
Fig. 7. Model of RET/PTC-mediated TRAF activation.
ΡΕΤ/ΠΤΧ διµερσ εξηιβιτ α γρεατερ αφφινιτψ φορ ΤΡΑΦ2 ανδ ΤΡΑΦ6 τηαν ΡΕΤ/ΠΤΧ µονοµερσ.
Τηε ΤΡΑΦ ιντεραχτιον ωιτη ΡΕΤ/ΠΤΧ δοεσ νοτ ρεθυιρε αν αχτιϖε χονφορµατιον οφ τηε κινασε
δοµαιν. Ηοωεϖερ, ΤΡΑΦ αχτιϖατιον δοεσ ρεθυιρε αν αχτιϖε κινασε δοµαιν χονφορµατιον ωηι
χη µοστ λικελψ ινδυχεσ ΤΡΑΦ ολιγοµεριζατιον το προµοτε ΝΙΚ ανδ ΝΦ−κB-mediated
proinflammatory signaling. The RET/PTC:TRAF:NIK:NF-κB pathway is functionally distinct from
Y588-mediated RAS and PI3K signaling cascades that promote transformation.
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